
Karen E Bremner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9453654/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Time Costs and Out-of-Pocket Costs in Patients With Chronic Hepatitis C inÂa Publicly Funded Health System. Value in Health, 2022, 25, 247-256.	0.3	3
2	Developing the Breast Utility Instrument, a preference-based instrument to measure health-related quality of life in women with breast cancer: Confirmatory factor analysis of the EORTC QLQ-C30 and BR45 to establish dimensions. PLoS ONE, 2022, 17, e0262635.	2.5	5
3	"Bring the Hoses to Where the Fire Is!†Differential Impacts of Marginalization and Socioeconomic Status on COVID-19 Case Counts and Healthcare Costs. Value in Health, 2022, 25, 1307-1316.	0.3	4
4	Impact of directâ€acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and metaâ€analysis. Journal of Viral Hepatitis, 2021, 28, 739-754.	2.0	23
5	Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study. CMAJ Open, 2021, 9, E897-E906.	2.4	5
6	Hepatitis C virus infection in First Nations populations in Ontario from 2006 to 2014: a population-based retrospective cohort analysis. CMAJ Open, 2021, 9, E886-E896.	2.4	2
7	Review and estimation of disutility for joint health states of severe and nonsevere hypoglycemic events in diabetes. Journal of Comparative Effectiveness Research, 2021, 10, 961-974.	1.4	2
8	Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study. CMAJ Open, 2021, 9, E167-E174.	2.4	9
9	Picturing ELSI+: a visual representation of ethical, legal, and social issues, and patient experiences in Health Technology Assessment in Canada. International Journal of Technology Assessment in Health Care, 2020, 36, 40-49.	0.5	0
10	A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C. Value in Health, 2020, 23, 127-137.	0.3	24
11	Patterns of Care and Costs for Older Patients With Colorectal Cancer at the End of Life: Descriptive Study of the United States and Canada. JCO Oncology Practice, 2020, 16, e1-e18.	2.9	7
12	Exploring the Benefits of Transformations in Health Utility Mapping. Medical Decision Making, 2020, 40, 183-197.	2.4	3
13	Comparing Childhood Cancer Care Costs in Two Canadian Provinces. Healthcare Policy, 2020, 15, 76-88.	0.6	2
14	Resource Utilization and Costs in Adolescents Treated for Cancer in Pediatric vs Adult Institutions. Journal of the National Cancer Institute, 2019, 111, 322-330.	6.3	12
15	New Insights into the Epidemiology of Prostate Cancer in Ontario. Cancer Investigation, 2019, 37, 513-523.	1.3	0
16	Home Dialysis is Associated with Lower Costs and Better Survival than other Modalities: A Population-Based Study in Ontario, Canada. Peritoneal Dialysis International, 2019, 39, 553-561.	2.3	33
17	The Bladder Utility Symptom Scale: A Novel Patient Reported Outcome Instrument for Bladder Cancer. Journal of Urology, 2018, 200, 283-291.	0.4	22
18	Costs of cancer care in children and adolescents in Ontario, Canada. Pediatric Blood and Cancer, 2017, 64, e26628.	1.5	15

KAREN E BREMNER

#	Article	IF	CITATIONS
19	Costs for Childhood and Adolescent Cancer, 90 Days Prediagnosis and 1 Year Postdiagnosis: A Population-Based Study in Ontario, Canada. Value in Health, 2017, 20, 345-356.	0.3	26
20	Benefits and harms of prostate cancer screening – predictions of the ONCOTYROL prostate cancer outcome and policy model. BMC Public Health, 2017, 17, 596.	2.9	12
21	Total and cancer-attributable phase-based costs for childhood cancer care: A population-based study in British Columbia, Canada Journal of Clinical Oncology, 2017, 35, 11-11.	1.6	1
22	Total and cancer-attributable phase-based costs for adolescent cancer care: A population–based study in British Columbia, Canada Journal of Clinical Oncology, 2017, 35, 12-12.	1.6	0
23	Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison. Healthcare Policy, 2017, 12, 95-108.	0.6	19
24	Phase-specific and lifetime costs of cancer care in Ontario, Canada. BMC Cancer, 2016, 16, 809.	2.6	71
25	The ONCOTYROL Prostate Cancer Outcome and Policy Model. Medical Decision Making, 2015, 35, 758-772.	2.4	8
26	An international comparison of costs of end-of-life care for advanced lung cancer patients using health administrative data. Palliative Medicine, 2015, 29, 918-928.	3.1	43
27	Discussion and Challenges in the Use andÂInterpretation of Utility Assessment. International Journal of Radiation Oncology Biology Physics, 2015, 91, 258-260.	0.8	Ο
28	A Review and Meta-analysis of Colorectal Cancer Utilities. Medical Decision Making, 2014, 34, 809-818.	2.4	45
29	Patient time and out-of-pocket costs for long-term prostate cancer survivors in Ontario, Canada. Journal of Cancer Survivorship, 2014, 8, 9-20.	2.9	39
30	A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada. Quality of Life Research, 2013, 22, 2951-2962.	3.1	22
31	Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study. CMAJ Open, 2013, 1, E1-E8.	2.4	85
32	Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study. CMAJ Open, 2013, 1, E151-E158.	2.4	37
33	Development and Validation of a Utility Weighting Function for the Patient-Oriented Prostate Utility Scale (PORPUS). Medical Decision Making, 2012, 32, 11-30.	2.4	27
34	Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?. BJU International, 2011, 108, 1588-1596.	2.5	25
35	End-of-Life Care for Lung Cancer Patients in the United States and Ontario. Journal of the National Cancer Institute, 2011, 103, 853-862.	6.3	86
36	Healthcare costs associated with prostate cancer: estimates from a populationâ€based study. BJU International, 2010, 105, 338-346.	2.5	91

#	Article	IF	CITATIONS
37	Measuring prostate-specific quality of life in prostate cancer patients scheduled for radiotherapy or radical prostatectomy and reference men in Germany and Canada using the Patient Oriented Prostate Utility Scale-Psychometric (PORPUS-P). BMC Cancer, 2009, 9, 295.	2.6	14
38	A Review and Meta-Analysis of Prostate Cancer Utilities. Medical Decision Making, 2007, 27, 288-298.	2.4	90
39	Management of Solitary 1 cm to 2 cm Liver Nodules in Patients with Compensated Cirrhosis: A Decision Analysis. Canadian Journal of Gastroenterology & Hepatology, 2007, 21, 491-500.	1.7	22
40	Responsiveness of disease-specific and generic utility instruments in prostate cancer patients. Quality of Life Research, 2007, 16, 509-522.	3.1	77
41	Marker states and a health state prompt provide modest improvements in the reliability and validity of the standard gamble and rating scale in prostate cancer patients. Quality of Life Research, 2007, 16, 1665-1675.	3.1	9
42	Patient and Community Preferences for Outcomes in Prostate Cancer. Medical Care, 2003, 41, 153-164.	2.4	113